B
Bullisch
Bullisch · 25%DNA
$11.62
Szenariopreis
$9.710
-0.291 (-3.00%)Zum Schluss
Loading chart…
- Hoch
- 10.140
- Eröffnung
- 9.690
- Volumengewichteter Durchschnittskurs
- 9.78
- Volumen
- 1.98M
- Marktkap.
- 683.73M
- Tief
- 9.500
- Umsatz
- 19.36M
- EV/EBITDA, TTM
- -4.49
Ginkgo Bioworks Holdings, Inc. offers biological research and development (R&D) services on its platform and autonomous laboratory to enable its customers to bring their products to market. The Company sells tools and biological R&D services across a range of industries to government and commercial customers. Its in-house autonomous lab is available as Cloud Lab through its Datapoints and Solutions contract research services. Its single segment, namely cell engineering, provides tools and biological R&D services across a range of industries. Its cell engineering customers work with biology to discover and manufacture new products across industries such as medicine, agriculture, industrial biotechnology and government. It provides R&D services spanning genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics. It provides a suite of microservices for product developers across industries that support bioengineers with protein engineering.
KI-Analyse of Ginkgo Bioworks Holdings Inc (DNA)
VerkaufenGinkgo Bioworks is not a good buy right now due to its significant financial struggles and negative market sentiment. The current price is $10.27, and the company reported a staggering 21% decline over the last five days. Additionally, the RSI is at 35.487, indicating oversold conditions but also reflecting weak momentum. The recent downgrade by TD Cowen, coupled with insider selling increasing by 74248.78%, suggests a lack of confidence in the company's near-term growth prospects, making it a risky investment at this time.
Analystenbewertungen (2)
+23.58% Aufwärtspotenzial
Verkaufen
0 Kaufen
0 Halten
2 Verkaufen
Aktuell: 9.71
Tief
12.00
Durchschnitt
12.00
Hoch
12.00
TD Cowen
Halten
$9
2026-08-07
TD Cowen
2026-08-07
Kursziel
$9
Halten
BTIG
Verkaufen
$5
2026-03-12
BTIG
2026-03-12
Kursziel
$5
Verkaufen
TD Cowen
Kaufen
$12
2026-01-08
TD Cowen
2026-01-08
Kursziel
$12
Kaufen
BTIG
Verkaufen
$9
2025-08-25
BTIG
2025-08-25
Kursziel
$9
Verkaufen
TD Cowen
Kaufen
$16
2025-08-08
TD Cowen
2025-08-08
Kursziel
$16
Kaufen
Bewertungskennzahlen
Das aktuelle erwartete KGV von Ginkgo Bioworks Holdings Inc (DNA) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von -6.41.
Alphio-AI-Kursszenarien für DNA
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Whales, die DNA halten
Event-Zeitleiste
News
7.510-09PRnewswireGinkgo Integrates Araceli's High-Throughput Imaging Technology
7.510-08NewsfilterGinkgo Bioworks Supports NSF X-Labs Program with Autonomous Lab Access
7.510-08PRnewswireGinkgo Bioworks Integrates Araceli's High-Throughput Imaging Technology
7.510-08PRnewswireAraceli and Ginkgo Enhance Cellular Imaging Capabilities
7.510-08PRnewswireGinkgo Integrates Araceli's Endeavor for Enhanced Cellular Data Generation
DNA FAQ – beantwortet von Alphio AI
Ginkgo Bioworks Holdings, Inc. offers biological research and development (R&D) services on its platform and autonomous laboratory to enable its customers to bring their products to market. The Company sells tools and biological R&D services across a range of industries to government and commercial customers. Its in-house autonomous lab is available as Cloud Lab through its Datapoints and Solutions contract research services. Its single segment, namely cell engineering, provides tools and biological R&D services across a range of industries. Its cell engineering customers work with biology to discover and manufacture new products across industries such as medicine, agriculture, industrial biotechnology and government. It provides R&D services spanning genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics. It provides a suite of microservices for product developers across industries that support bioengineers with protein engineering. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Ginkgo Bioworks is not a good buy right now due to its significant financial struggles and negative market sentiment. The current price is $10.27, and the company reported a staggering 21% decline over the last five days. Additionally, the RSI is at 35.487, indicating oversold conditions but also reflecting weak momentum. The recent downgrade by TD Cowen, coupled with insider selling increasing by 74248.78%, suggests a lack of confidence in the company's near-term growth prospects, making it a risky investment at this time.
2 analysts cover DNA: 0 rate it Buy, 0 Hold and 2 Sell. The average price target is 12.00.
Community
Mehr ↗
$RT1 $DOGE 🚨 DNA IS TESTING A MAJOR RESISTANCE...... A BREAKOUT COULD CHANGE THE PICTURE! 📈 $DNA Buyers have stepped back in, and RSI(6) near 55 suggests mildly bullish momentum. However, the recent rejection near $0.22011 shows that sellers are still defending higher prices. 📈 If buyers break above $0.22011 with strong volume, the price could move toward $0.23180. But if resistance holds and momentum fades, DNA may pull back toward $0.19120, with $0.17168 as the key support to watch. 👀 Key levels to watch: 🟢 Support: $0.19120 – $0.17168 🔴 Resistance: $0.22011 – $0.23180 ⚠️ Don’t mistake a bounce for a confirmed breakout. Wait for confirmation and always manage your risk. $DNA
Mehr anzeigen
The account equity curve looks really satisfying. I just love it when Bitcoin drops sharply $BTC. I'm still holding on to $DNA, waiting for it to make its move.
Mehr anzeigen
$DNA DUMPS 27% | BEARISH TARGET IN SIGHT My October 19 bearish setup on #DNA continues to play out, with price now down to $0.19074, a ~27% drop from our short setup's breakdown exit point. Updated Technical Analysis: ➤ Current Price: $0.19074 ➤ Bearish Target: $0.148 ➤ Key Resistance: $0.250 ➤ Bearish Outlook: Still watching for further downside toward $0.148. The chart is doing the talking. Hope you're enjoying the analysis. Stay tuned for the next update.
Mehr anzeigen
Gate Futures Listings | October 12–18, 2026 One-stop access to popular memes, crypto assets, stocks, and ETFs. 🔹 New: 14 futures trading pairs. As of now, Gate supports trading 482+ stock futures. 🔹 Last week's highlights: $DNA, $BATON, $CLAUDIA, $SBUX, and other futures tokens. 🔹 Long and short positions support up to 20x leverage, helping you respond flexibly to market conditions. 🔹 Join popular futures events to earn more rewards. Stock Futures Bonus Season: Share a 500,000 USDT prize pool, with up to 1,000 USDT per person. ChangXin Memory and Unitree Robotics futures trading competition: register to receive 5 USDT, with up to 240 USDT per person.
Mehr anzeigen
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.